(Q53537670)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10563212%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Treatment with interferon beta-1b improves quality of life in multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10563212%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

0 references

1 reference

G P Rice

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10563212%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

J Oger

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10563212%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

P Duquette

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10563212%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

G S Francis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10563212%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

M Bélanger

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10563212%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

S Laplante

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10563212%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

J F Grenier

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10563212%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 November 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10563212%20AND%20SRC:MED&resulttype=core&format=json

Canadian Journal of Neurological Sciences

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10563212%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10563212%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10563212%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

276-282

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10563212%20AND%20SRC:MED&resulttype=core&format=json

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS031716710000038X

7 January 2021

Burden of illness of multiple sclerosis: Part I: Cost of illness. The Canadian Burden of Illness Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS031716710000038X

7 January 2021

Natural history of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS031716710000038X

7 January 2021

Impact of aerobic training on fitness and quality of life in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1017%2FS031716710000038X

7 January 2021

Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey

1 reference

https://api.crossref.org/works/10.1017%2FS031716710000038X

7 January 2021

The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis

1 reference

https://api.crossref.org/works/10.1017%2FS031716710000038X

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1017%2FS031716710000038X

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS031716710000038X

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS031716710000038X

7 January 2021

1 reference

https://api.crossref.org/works/10.1017%2FS031716710000038X

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS031716710000038X

7 January 2021

Cognitive dysfunction in multiple sclerosis.: II. Impact on employment and social functioning

1 reference

https://api.crossref.org/works/10.1017%2FS031716710000038X

7 January 2021

SPECT, MRI and cognitive functions in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS031716710000038X

7 January 2021

10.1017/S031716710000038X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10563212%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference